The coronavirus disease 2019 (COVID-19) pandemic has demonstrated the impact of the biopharmaceutical industry’s performance in the area of innovation.
By Teodoro B. Padillahe coronavirus disease 2019 pandemic has demonstrated the impact of the biopharmaceutical industry’s performance in the area of innovation. Within a year, for example, a COVID-19 vaccine was developed, and the succeeding months showed biopharmaceutical companies scale up manufacturing for wider vaccines’ reach. Important treatment innovations for mild, moderate and severe cases were also developed and made available. As a result of these, millions of lives were saved.
In the Novartis Annual Results Press Conference held this month, the Swiss company’s CEO Vas Narasimhan said that fewer than 10% of diseases known to affect humans are currently treatable. Globally, people also live an average of 10 years with a disease or disability. Yet new treatments broadly still reach only a fraction of eligible patients, and manageable conditions like heart disease cause millions of avoidable deaths each year.
“Our performance in 2022 showed that we are making progress in addressing society’s greatest disease burdens,” Mr. Narasimhan said. “Our focus on cardiovascular diseases, for example, gives countries and healthcare systems solutions to address the world’s leading cause of death and disability.” With this, Novartis was the first to sign up as a partner for the Access to Oncology Medicines Coalition, a global partnership launched by the Union for International Cancer Control in 2022, The goal of this partnership is to increase access to quality-assured essential cancer medicines in low- and lower middle-income countries ,
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Marcos meets council to advance PH's culture of innovationPresident Ferdinand “Bongbong” Marcos Jr. had his first meeting with the National Innovation Council (NIC) to discuss the implementation of the Philippine Innovation Act.
Read more »
Innovation council approved 19 projects worth P115M — NEDA chiefThe National Innovation Council (NIC) has approved 19 project proposals which will be funded through grants under the P200-million Innovation Fund, National Economic and Development Authority (NEDA) Secretary Arsenio Balisacan said Tuesday.
Read more »
NIC clears Innovation Fund drawdown for 19 projects | Cai U. OrdinarioTHE National Innovation Council (NIC) has approved 19 projects to tap into the government’s Innovation Fund, according to the National Economic and Development Authority (Neda). In a briefing in Malacañang, Neda Secretary Arsenio M. Balisacan said the 19 projects will draw P115 million from the Innovation Fund. Balisacan said the…
Read more »
Aboitiz Land pushes innovation in construction with first precast panel installations at The Villages at Lipa | BMPlusAboitiz Land, the real estate arm of the Aboitiz group of companies, raised the bar for residential development by installing the first-ever precast panels by SMCC Philippines on homes being built at The Villages at Lipa. This latest update on the development is set to delight future homeowners as they…
Read more »
Metro Manila’s COVID-19 positivity rate slightly up to 1.7% — OCTAMANILA, Philippines — The COVID-19 positivity rate in Metro Manila slightly rose from 1.6 to 1.7 percent, according to OCTA Research fellow Guido David on Monday. “NCR (National Capital
Read more »
NCR COVID-19 positivity rate rose slightly to 1.7% —OCTAThe seven-day COVID-19 positivity rate in the National Capital Region (NCR) went up slightly from 1.6% as of Feb. 11 to 1.7% as of Feb. 18, OCTA Research said on Monday.
Read more »